Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)

Status unconfirmed

Conditions studied: Prostate Cancer Metastatic

In brief

This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastasis.

Key facts

Study ID

NCT03414437

Run by

Carolina Research Professionals, LLC

People needed

31

Starts

2017-10-01

Expected to finish

2021-10-01

Last updated by the study team

2019-03-19

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Eligible subjects are adults over the age of 18 with mCRPC that completed the eRADicAte study. The living study subject or legally authorized representative must be able to understand and sign the written informed consent form.

You may not qualify if…

• A living study subject or his legally authorized representative are not able to understand or willing to sign the written informed consent form.

Where it is running

• Chesapeake urology Research Associates — Towson, Maryland, United States
• Urology Cancer Center and GU Research Network — Omaha, Nebraska, United States
• Associated Medical Professionals — Syracuse, New York, United States
• Oregon Urology Institute — Springfield, Oregon, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.